Zura Bio Limited (NASDAQ: ZURA) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
Zura Bio Limited (NASDAQ: ZURA) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $15.00 price target on the stock.
Zura Bio Limited (NASDAQ: ZURA) had its price target lowered by analysts at Chardan Capital from $12.00 to $10.00. They now have a "buy" rating on the stock.
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates
Zura Bio to Present at the Leerink Partners Global Healthcare Conference